Key Trend Reshaping the RNA Targeting Small Molecule Drug Discovery Market in 2025: Revolutionizing Small-Molecule Drug Discovery Through The Impact Of AI integration In Pharmaceutical Research

What combination of drivers is leading to accelerated growth in the rna targeting small molecule drug discovery market?
The rise in the rates of cancer, genetic anomalies, and viral infections are anticipated to catalyze the expansion of the RNA-targeted small-molecule drug discovery market. Cancer constitutes a spectrum of ailments typified by uncontrolled cell multiplication in the body, while viral infections are caused by miniscule infectious particles capable of reproduction only within living cells. Drug discovery based on RNA targeting is utilized to combat cancer, genetic disorders, and viral infections, given the correlation of these diseases with genes and defective genetic material, which could be treated with drugs developed through RNA-targeted techniques. For instance, a February 2024 study by the Switzerland- established World Health Organization (WHO) revealed that there were around 20 million new instances of cancer and 9.7 million deaths worldwide in 2022. Lung cancer topped the list with 2.5 million new cases (12.4%), followed by female breast cancer (2.3 million cases, 11.6%), colorectal cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970,000 cases, 4.9%). By 2050, it's projected that new cancer cases would escalate by 77%, hitting over 35 million per year. Consequently, the escalating prevalence of cancer, genetic disorders, and viral infections are fuelling the growth of the RNA-targeted small-

Get Your RNA Targeting Small Molecule Drug Discovery Market Report Here:
https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

What is the projected compound annual growth rate (CAGR) of the rna targeting small molecule drug discovery market from 2025 to 2034, and what factors influence it?
The market size of RNA targeting small molecule drug discovery has witnessed substantial growth recently. The forecast indicates that it will expand from $1.76 billion in 2024 to $2.14 billion in 2025, presenting a compound annual growth rate (CAGR) of 21.8%. The past growth can be attributed to factors such as enhanced comprehension of disease genetics, findings in genomics and proteomics, challenges in drug resistance, investment in biotechnological and pharmaceutical research, and the emergence of RNA therapeutics.

In the coming years, the RNA targeting small molecule drug discovery market is predicted to see a dramatic increase in size. It is anticipated to expand to a value of $4.92 billion by 2029, experiencing a compound annual growth rate (CAGR) of 23.1%. This anticipated growth, during the forecast period, can be linked to factors such as the development of RNA epigenetics research, RNA-seq and functional genomics, the incorporation of artificial intelligence (AI), the focus on patient-centric methodologies, and the use of exosome-mediated drug delivery. The forecast period is also expected to see major trends emerging, which includes the development of RNA editing technologies, advancements in CRISPR technology, technological innovations, progression in RNA biology, and the application of RNA targeting in neurodegenerative diseases.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12480&type=smp

What trends are poised to drive the future success of the rna targeting small molecule drug discovery market?
The inclusion of Artificial Intelligence (AI) in the process of drug discovery is emerging as a major trend in the small-molecule drug discovery market. Big players in this market are utilizing AI technologies to hasten their drug discovery operations in a bid to maintain their market standing. As an example, in May 2023, Google's cloud computing division, Google Cloud, introduced the Target and Lead Identification Suite and the Multiomics Suite to aid in the drug discovery process. The Multiomics Suite speeds up the process of identifying and analyzing genetic data, thereby helping companies develop precision medicines. The Target and Lead Identification Suite helps researchers gain a more in-depth knowledge of amino acids' role and make predictions about protein structures.

What are the major segments of the rna targeting small molecule drug discovery market and their role in driving growth?
The RNA targeting small molecule drug discovery market covered in this report is segmented -

1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)
2) By Technology: CRISPR-Cas9, RNA Aptamers, Small Interfering RNA (siRNA), Ribozymes, Other Technologies
3) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas
4) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods
5) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications

Subsegments:
1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding, Modulation Of mRNA Stability, mRNA Translation Inhibition
2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA, Small Nuclear RNA, Small Nucleolar RNA
3) By MicroRNA (miRNA): miRNA Inhibition, miRNA Mimics, Targeting Specific miRNA Pathways
4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators, Targeting Specific lncRNA Functions, Therapeutic Applications Of lncRNA

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12480

Which regions are key players in the growth of the rna targeting small molecule drug discovery market?
North America was the largest region in the RNA-targeting small molecule drug discovery market in 2024. The regions covered in the RNA targeting small molecule drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Who are the key firms paving the way for growth in the rna targeting small molecule drug discovery market?
Major companies operating in the RNA targeting small molecule drug discovery market include F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Moderna Inc., Astellas Pharma Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, Arbutus Biopharma Corporation, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12480&type=smp

What Is Covered In The RNA Targeting Small Molecule Drug Discovery Global Market Report?

• Market Size Forecast: Examine the rna targeting small molecule drug discovery market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the rna targeting small molecule drug discovery market for a structured understanding.
• Key Players Overview: Analyze major players in the rna targeting small molecule drug discovery market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the rna targeting small molecule drug discovery market.
• Segment Contributions: Evaluate how different segments drive overall growth in the rna targeting small molecule drug discovery market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the rna targeting small molecule drug discovery market.
• Industry Challenges: Identify potential risks and obstacles affecting the rna targeting small molecule drug discovery market.
• Competitive Landscape: Review strategic developments in the rna targeting small molecule drug discovery market, including expansions, agreements, and new product launches.

Learn More About The Business Research Company
The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.